July 2017 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2015/16 Invitation to Tender, dated 6 November 2015 and the 2016/17 Invitation to Tender, dated 3 November 2016.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (http://www.pgnz.org.nz/pharmacode) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (http://www.nzulm.org.nz/sponsors(external link)). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2015/16 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2019
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
1. Tenders awarded to listed pharmaceuticals where no brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Pack price |
Hospital Supply Brand (Supplier) | DV Limit | Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|
| Droperidol | Inj 2.5 mg per ml, 1 ml ampoule, 10 ampoules | $35.00 | Droperidol Panpharma (Multichem) | 1% | 1 April 2018 | 1 June 2018 |
2016/17 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2020
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
2. Tenders awarded to listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current pack price |
New pack price |
Sole supply brand (Supplier) |
Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Amitriptyline* | Tab 10 mg, 100 tablets, blister pack | $1.68 | $1.96 | Arrow-Amitriptyline (Actavis) |
1 February 2018 | 1 May 2018 |
| Amitriptyline* | Tab 25 mg, 100 tablets, blister pack | $1.68 | $1.52 | Arrow-Amitriptyline (Actavis) |
1 February 2018 | 1 May 2018 |
| Amitriptyline* | Tab 50 mg, 100 tablets, blister pack | $2.82 | $2.51 | Arrow-Amitriptyline (Actavis) |
1 February 2018 | 1 May 2018 |
| * These products will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b) (II) of the 2016/17 Invitation To Tender | ||||||
3. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current pack price |
New pack price |
Sole Supply Brand (Supplier) |
Date of listing/ subsidy change for tender winning brand |
Date of reference pricing of other listed brands |
Sole Subsidised Supply date (and delisting of other listed brands) |
Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
| Amoxicillin | Oral liquid 125 mg per 5 ml, 100 ml bottle |
$0.88* | $1.20 | Alphamox 125 (Myan) |
1 December 2017 | N/A | 1 May 2018 | Ospamox (Sandoz) Amoxicillin Actavis (Actavis) |
| Amoxicillin | Oral liquid 250 mg per 5 ml, 100 ml bottle |
$0.97* | $1.31 | Alphamox 250 (Mylan) |
1 December 2017 | N/A | 1 May 2018 | Ospamox (Sandoz) Amoxicillin Actavis (Actavis) |
| * Note the price/subsidy of these products is higher for Ospamox | ||||||||
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
4. Tenders awarded to listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current pack price |
New pack price |
Hospital Supply Brand (Supplier) |
DV Limit | Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
| Amitriptyline* | Tab 10 mg, 100 tablets, blister pack | $1.68 | $1.96 | Arrow-Amitriptyline (Actavis) | 1% | 1 February 2018 | 1 April 2018 |
| Amitriptyline* | Tab 25 mg, 100 tablets, blister pack | $1.68 | $1.52 | Arrow-Amitriptyline (Actavis) | 1% | 1 February 2018 | 1 April 2018 |
| Amitriptyline* | Tab 50 mg, 100 tablets, blister pack | $2.82 | $2.51 | Arrow-Amitriptyline (Actavis) | 1% | 1 February 2018 | 1 April 2018 |
| * These products will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b) (II) of the 2016/17 Invitation To Tender | |||||||
5. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current pack price |
New pack price |
Hospital Supply Brand (Supplier) |
DV Limit | Listing date | Hospital Supply Status date | Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
| Amoxicillin | Oral liq 125 mg per 5 ml, 100 ml bottle |
$0.88* | $1.20 | Alphamox 125 (Myan) |
1% | 1 December 2017 | 1 February 2018 | Ospamox (Sandoz) Amoxicillin Actavis (Actavis) |
| Amoxicillin | Oral liq 250 mg per 5 ml, 100 ml bottle |
$0.97* | $1.31 | Alphamox 250 (Myan) |
1% | 1 December 2017 | 1 February 2018 | Ospamox (Sandoz) Amoxicillin Actavis (Actavis) |
| * Note the price/subsidy of these products is higher for Ospamox | ||||||||
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2015/16 Invitation to Tender, dated 6 November 2015, and
- the 2016/17 Invitation to Tender, dated 3 November 2016.
2015/16 Invitation to Tender
| Chemical name | Line item |
|---|---|
| Baclofen | Inj 2 mg per ml, 5 ml |
| Mycophenolate mofetil | Cap 250 mg |
| Mycopheolate mofetil | Tab 500 mg |
2016/17 Invitation to Tender
| Chemical name | Line item |
|---|---|
| Aprepitant | Cap 2 x 80 mg and 1 x 125 mg |
| Bumetanide | Tab 1 mg |
| Ceftazidime | Inj 2 g |
| Doxycycline hydrochloride | Tab 100 mg |
For products included in the 2015/16 and 2016/17 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.